🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We are excited to lead the latest round in Formation Bio, an AI-native pharma company going after the major bottleneck in drug development through a best-in-class team, novel platform, and stellar partnerships. The company has already built capabilities and expertise within the

We’re thrilled to be partnering with the Formation Bio team! Formation Bio is building a tech and AI-native pharma company differentiated by radically more efficient drug development. Co-founders Ben Liu and linhao have built a team that brings together the best across

Honored to be part of Endpoints News list of top 11 most promising biopharmas! We're laser focused on bringing new treatments to patients faster and more efficiently by building a tech and AI driven pharma company. Join us: formation.bio/careers#job-op…

Meet Muse - our AI tool for patient recruitment strategy & content creation, built together w. Sanofi and OpenAI. We believe AI systems like Muse will enable us to drastically reduce cost + time of bringing new medicines to patients. endpts.com/sanofi-openai-…

Meet Muse, our latest AI innovation for drug development—a tool designed to optimize patient recruitment built together w. Sanofi and OpenAI. Muse is an example of how AI systems are becoming capable of performing tasks that once required entire teams or organizations.

Great example of a tangible AI use case in one of the most intractable problem areas - drug development. Congrats Formation Bio

“If we think about all the drug development activities, we think there’s a Muse for everything,” Formation Bio CEO Benjamine Liu said. “This all ladders up to a broader AI R&D scientist.” A bold claim for a big vision from Liu — but a first step here: endpts.com/sanofi-openai-…

fiercebiotech.com/cro/sanofi-for…

Our CDO Gavin Corcoran will be presenting at Bloomberg's AI & Drug Development Forum next week in NYC! Learn more and register to attend here: go.bloomberg.com/attend/invite/… Other presenters include: Owkin Certara Flagship Pioneering Clario Insilico Medicine Parexel

We're delighted to have contributed to this white paper published today by World Economic Forum and ZS exploring AI’s potential to revolutionize clinical development. The themes explored in this paper align deeply with our mission to harness AI for transformative advances in drug

Tune in tomorrow World Economic Forum as our Co-Founder & CEO Ben Liu discusses the future of AI-driven organizations, together with: - CNBC's Dan Murphy - Imbue's Kanjun 🐙 - Lead Edge Capital's Mitchell Green - Lattice's Sarah Franklin - you.com's Richard Socher

Some highlights from Formation Bio CEO & Co-Founder Ben Liu at this morning's panel discussion at World Economic Forum about how companies - and entire industries - are positioned to scale with AI in unprecedented ways. You can find the full recording here: lnkd.in/eHabZm9B

At Formation Bio, we're building AI systems to accelerate and improve drug development. Our latest blog dives into Muse, our AI tool that transforms patient recruitment, creating recruitment strategy and materials in a matter of minutes. formation.bio/blog/behind-th…

Check out Part 2 of our blog series that goes "behind the scenes" of Muse, our GenAI-powered recruitment tool that streamlines patient recruitment for clinical trials. formation.bio/blog/behind-th…

Exclusive: Ex-Pfizer CSO Mikael Dolsten joins Formation Bio to guide drug strategy — and shape how its AI makes R&D bets. endpts.com/exclusive-form…

Formation Bio welcomes our first class of Entrepreneurs in Residence! These dealmaking veterans will help drive pipeline growth, partnerships & BD strategy. Read more here: formation.bio/blog/welcoming…

Excited to be named to CNBC Disruptors 50 List this year. As AI disrupts every industry, we're proud to be leading the way for drug development. cnbc.com/cnbc-disruptor…

The future of drug development is AI-native, and we're leading the charge. Hear more from our Co-Founder & CEO Ben Liu on CNBC CNBC's Fast Money youtube.com/watch?v=S52cNc…

This morning we announced the license of gusacitinib, a dual JAK/SYK inhibitor, to Sanofi! We are excited that this transaction with Sanofi ushers gusacitinib into its next stage of development. You can read more here: prnewswire.com/news-releases/…